Registo

Para usufruir de todas as funcionalidades do site APEF deverá estar registado.

Quero registar-me
15.02.2016

FDA Expands Use of HCV Drug Daclatasvir (Daklinza)

The US Food and Drug Administration (FDA) has approved expanded use of the NS5A replication complex inhibitor daclatasvir (Daklinza, Bristol-Myers Squibb) for hepatitis C virus (HCV) infection.

Consulte a notícia completa: clique aqui.